These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12046041)

  • 1. Analysis of renal bone disease treatment in dialysis patients.
    Johnson CA; McCarthy J; Bailie GR; Deane J; Smith S
    Am J Kidney Dis; 2002 Jun; 39(6):1270-7. PubMed ID: 12046041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey.
    Martin CJ; Reams SM
    J Ren Nutr; 2003 Apr; 13(2):133-6. PubMed ID: 12671837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bone and mineral disorder of children undergoing chronic peritoneal dialysis.
    Borzych D; Rees L; Ha IS; Chua A; Valles PG; Lipka M; Zambrano P; Ahlenstiel T; Bakkaloglu SA; Spizzirri AP; Lopez L; Ozaltin F; Printza N; Hari P; Klaus G; Bak M; Vogel A; Ariceta G; Yap HK; Warady BA; Schaefer F;
    Kidney Int; 2010 Dec; 78(12):1295-304. PubMed ID: 20811335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation.
    Changsirikulchai S; Domrongkitchaiporn S; Sirikulchayanonta V; Ongphiphadhanakul B; Kunkitti N; Stitchantrakul W; Radienahamed P
    J Med Assoc Thai; 2000 Oct; 83(10):1223-32. PubMed ID: 11143489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influences of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan.
    Yokoyama K; Katoh N; Kasai K; Kubo H; Murai S; Shoji R; Imamura N; Saika S; Yumita S; Ishida M; Takasu S; Kono T; Yoshida Y; Wakabayashi T; Kimua Y; Hosoya T
    Ther Apher Dial; 2006 Jun; 10(3):257-61. PubMed ID: 16817790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
    Fournier A; Morinière P; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephrologie; 1995; 16(2):165-90. PubMed ID: 7753302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal osteodystrophy in dialysis patients as estimated by three-point bone densitometry].
    Kucharska E; Stompór T; Sułowicz W; Drozdz M; Kaczmarczyk I; Szymczakiewicz-Multanowska A; Chruściel B; Kraśnicka M
    Przegl Lek; 2000; 57(6):334-9. PubMed ID: 11107868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.